Picture of Fulcrum Therapeutics logo

FULC Fulcrum Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Fulcrum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-80.8-110-97.3-9.72-74.9
Depreciation
Non-Cash Items11.713.58.8110.29.52
Other Non-Cash Items
Changes in Working Capital-11.9-3.09-4.61-4.253.91
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-78.5-97-91-2.22-60.1
Capital Expenditures-1.71-1.96-0.508-0.278-0.314
Purchase of Fixed Assets
Other Investing Cash Flow Items-12814.4-36.232.531
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-13012.4-36.732.230.7
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities18784.31182.75169
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-21.6-0.314-9.5432.8139